Raised $17M across disclosed rounds.[10]

Series A closed August 2024, led by Spring Tide Capital.[2][3][4][13]

post-money valuation is not publicly disclosed.

Named investors include Oyster Ventures, Spring Tide Capital, Access Capital, Seamless Capital, Goat Rodeo Capital, Seaside Ventures.[1][2][3][4][12][13]

Zack Abbott, Co-founder & CEO[10][15][23][16][24]

Katie U., Sr. Manager, Product Quality[15][16][23][24]

PERKii · perkii.com · Same buyer and same job to be done: a consumer buying a functional probiotic beverage for gut benefit, evaluated against ZBiotics' probiotic drinks in the same retail and DTC shelf set. VentureRadar lists PERKii as a similar company to ZBiotics.[18]

BiomEdit · biomedit.com · Same technical wedge, different buyer: a buyer evaluating engineered probiotics as a commercial category would weigh BiomEdit as the closest parallel on the engineering approach, though its customer is poultry producers rather than consumers.[18]

BLIS Technologies · blistechnologies.com · Same buyer and same shelf: a consumer or retail buyer choosing a branded probiotic strain product, and a partner sourcing probiotic ingredients, would evaluate BLIS against ZBiotics' strain-based consumer products.[18]

The customer proof is company-sourced only. No independent source in this ledger confirms it.[14]

Ask for one referenceable production customer.

Not a recommendation. The first thing this ledger cannot answer.

Filled in the side panel for invited readers. This card carries sourced facts only.